Study S001422

Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients

Included trial: extracted data ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT02324842
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: COMPLETED
Enrollment: 45
Start: 2014-11
Primary completion: 2018-03-28
Lead sponsor: The University of Texas Health Science Center at San Antonio
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Canagliflozin; DRUG:Liraglutide
Results posted: TRUE
Secondary identifiers: OTHER:HSC20140322H

Registered primary outcomes

HbA1c at 4 Months [Approximately 4 months]
Fasting Plasma Glucose (FPG) at 4 Months [Baseline to Approximately 4 months]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0024127	Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM. Ali AM, The Journal of clinical endocrinology and metabolism	2020	Other	PMID 32745202 DOI	cites ClinicalTrials.gov:NCT02324842; registry reference DERIVED:32745202
R0024524	Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes. Ali AM, Diabetes care	2020	Randomized trial	PMID 32220916 DOI	cites ClinicalTrials.gov:NCT02324842; registry reference DERIVED:32220916